Gemmus Pharma Inc. Company Profile

News Articles [ 1189 Associated News Articles listed on BioPortfolio]

Gemmus Pharma completes venture financing

Gemmus Pharma Closes on Series A Funding to Develop Superior Flu Drug

Gemmus Pharma Inc. announced today that it has closed on a Series A funding. Gemmus is a privately held biotechnology company developing an improved host-targeted treatment for in...

Gemmus Pharma to Present New Data at 26th Annual International Society for Antiviral Research (ICAR) Meeting in San Francisco, May 13

Gemmus Pharma Inc. ("Gemmus") will present results from its initial studies designed to evaluate the use of GP1001 in influenza at the 26th International Conference on Antiviral R...

Gemmus Pharma Adds Life Science Industry Experts to Board of Directors

Gemmus Pharma Inc. a privately held biotechnology company developing an improved host-targeted treatment for flu, today announced the appointment of three new directors, Christoph...

Pharma 3.0 Pulls Companies into the Digital Future

Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0.  Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drug...

Big pharma companies BMS and Merck are pharma partnering on Daclatasvir

Big pharma company, Bristol-Myers Squibb, is pharma partnering with another big pharma company, Merck, to develop Daclatasvir to treat Hepatitis C. The big pharma companies will work on the hepatitis...

Merck enter pharma partnering pact with Ra Pharma for cyclomimetics

Ra Pharmaceuticals has entered into a pharma partnering deal with Merck, a top 50 big pharma corporation, focused on the development of Cyclomimetics, a new class of compounds that have the diversity...

Verona Pharma plc: Analyst Presentation on the Company Website

LONDON, April 10, 2013 /PRNewswire/ -- Verona Pharma plc ("Verona Pharma" or the "Company") Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology co...

Drugs and Medications [ 238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [ 56 Associated PubMed Articles listed on BioPortfolio]

Comment about the article "Psychopharmaceuticals and diabetes" of Ress C, Tschoner A, Kaser S, and Ebenbichler CF in Wiener Medizinische Wochenschrift 2011; 161/21-22: 531-42.

Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore.

Structures containing the (R)-3-amino-3-methyl piperidine unit as a new pharmacophore moiety have been shown to possess moderate inhibitory activity for DPP-4 with good pharmacokinetics profile. One o...

Is pharma running out of brainy ideas?

Big pharma moves from 'blockbusters' to 'niche busters'.

China spurs pharma innovation.

Clinical Trials [ 35 Associated Clinical Trials listed on BioPortfolio]

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

This is 2-armed parallel group, prospective, randomized, open-label, multicenter Phase 3 controlled trial to establish the efficacy and safety of conversion from maintenance immunosuppress...

Development of a New Method for Analgesia

Aim: To examine a new method to perform local anesthesia in order to diminish the inconvenience by the procedure in patients before performing intubation or oesophagogastroduodenoscopy.

Companies [ 591 Associated Companies listed on BioPortfolio]

Gemmus Pharma Inc.

Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of infectious diseases by modulating the host r...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

Laurantis Pharma Oy

Laurantis Pharma Oy is a privately held specialty pharmaceutical company based in Finland. Laurantis Pharma Oy was formed in 2010 through the merger of two independent companies,...

FranceMed Pharma

FranceMed Pharma is a Research, Development, FMCG Manufacturer and Global Marketing Company established since 1981. FranceMed Pharma owns Magicool® brand and the world-wide patents and technology. Fr...